Methodological challenges in pragmatic trials in Alzheimer's disease and related dementias: Opportunities for improvement

被引:6
|
作者
Taljaard, Monica [1 ,2 ]
Li, Fan [3 ]
Qin, Bo [3 ]
Cui, Caroline [3 ]
Zhang, Leyi [3 ]
Nicholls, Stuart G. [1 ]
Carroll, Kelly [1 ]
Mitchell, Susan L. [4 ]
机构
[1] Ottawa Hosp Res Inst, Clin Epidemiol Program, Civ Campus,1053 Carling Ave,Civ Box 693, Ottawa, ON K1Y 4E9, Canada
[2] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada
[3] Yale Univ, Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[4] Hebrew Senior Life Marcus Inst Aging Res, Boston, MA USA
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
Cluster randomized trials; longitudinal data analysis; multilevel modeling; missing data; intracluster correlation; pragmatic trials; Alzheimer's disease; dementia; COVARIATE-DEPENDENT MISSINGNESS; SAMPLE-SIZE DETERMINATION; CLINICAL-TRIALS; OUTCOMES; DESIGN; POWER;
D O I
10.1177/17407745211046672
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background and Aims We need more pragmatic trials of interventions to improve care and outcomes for people living with Alzheimer's disease and related dementias. However, these trials present unique methodological challenges in their design, analysis, and reporting-often, due to the presence of one or more sources of clustering. Failure to account for clustering in the design and analysis can lead to increased risks of Type I and Type II errors. We conducted a review to describe key methodological characteristics and obtain a "baseline assessment" of methodological quality of pragmatic trials in dementia research, with a view to developing new methods and practical guidance to support investigators and methodologists conducting pragmatic trials in this field. Methods We used a published search filter in MEDLINE to identify trials more likely to be pragmatic and identified a subset that focused on people living with Alzheimer's disease or other dementias or included them as a defined subgroup. Pairs of reviewers extracted descriptive information and key methodological quality indicators from each trial. Results We identified N = 62 eligible primary trial reports published across 36 different journals. There were 15 (24%) individually randomized, 38 (61%) cluster randomized, and 9 (15%) individually randomized group treatment designs; 54 (87%) trials used repeated measures on the same individual and/or cluster over time and 17 (27%) had a multivariate primary outcome (e.g. due to measuring an outcome on both the patient and their caregiver). Of the 38 cluster randomized trials, 16 (42%) did not report sample size calculations accounting for the intracluster correlation and 13 (34%) did not account for intracluster correlation in the analysis. Of the 9 individually randomized group treatment trials, 6 (67%) did not report sample size calculations accounting for intracluster correlation and 8 (89%) did not account for it in the analysis. Of the 54 trials with repeated measurements, 45 (83%) did not report sample size calculations accounting for repeated measurements and 19 (35%) did not utilize at least some of the repeated measures in the analysis. No trials accounted for the multivariate nature of their primary outcomes in sample size calculation; only one did so in the analysis. Conclusion There is a need and opportunity to improve the design, analysis, and reporting of pragmatic trials in dementia research. Investigators should pay attention to the potential presence of one or more sources of clustering. While methods for longitudinal and cluster randomized trials are well developed, accessible resources and new methods for dealing with multiple sources of clustering are required. Involvement of a statistician with expertise in longitudinal and clustered designs is recommended.
引用
收藏
页码:86 / 96
页数:11
相关论文
共 50 条
  • [41] Editorial: Methods and applications in Alzheimer's disease and related dementias
    Yogi, Alvaro
    Grosso, Carlos Ayala
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [43] The Broad Range of Research in Alzheimer’s Disease and Related Dementias
    Steven T. DeKosky
    Ranjan Duara
    Neurotherapeutics, 2022, 19 : 1 - 7
  • [44] Alzheimer's disease and related dementias: important policy issues
    Stone, RI
    AGING & MENTAL HEALTH, 2001, 5 : S146 - S148
  • [45] Treatment and care strategies for Alzheimer's disease and related dementias
    Foerstl, H.
    NERVENARZT, 2008, 79 (05): : 617 - 628
  • [46] THE PRESCRIPTION DRUG LANDSCAPE OF ALZHEIMER'S DISEASE AND RELATED DEMENTIAS
    Bangerter, Lauren
    Clark, Callahan
    Jarvis, Megan
    Coates, Emma
    Sheils, Natalie
    Wong, Alyssa
    Cohen, Ken
    INNOVATION IN AGING, 2022, 6 : 468 - 468
  • [47] Sleep in Persons Living with Alzheimer's Disease and Related Dementias
    Ordonez, Maria de los Angeles
    Ordonez, Patricia de los Angeles
    NURSING CLINICS OF NORTH AMERICA, 2021, 56 (02) : 249 - 263
  • [48] Editorial: Insights in Alzheimer's disease and related dementias: 2022
    Ibanez, Agustin
    Reiss, Allison B.
    Custodio, Nilton
    Agosta, Federica
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [49] Identification of circRNAs linked to Alzheimer's disease and related dementias
    Puri, Sambhavi
    Hu, Junming
    Sun, Zhuorui
    Lin, Mintao
    Stein, Thor D.
    Farrer, Lindsay A.
    Wolozin, Benjamin
    Zhang, Xiaoling
    ALZHEIMERS & DEMENTIA, 2023, 19 (08) : 3389 - 3405
  • [50] The structural and social determinants of Alzheimer's disease related dementias
    Adkins-Jackson, Paris B.
    George, Kristen M.
    Besser, Lilah M.
    Hyun, Jinshil
    Lamar, Melissa
    Hill-Jarrett, Tanisha G.
    Bubu, Omonigho M.
    Flatt, Jason D.
    Heyn, Patricia C.
    Cicero, Ethan C.
    Zarina Kraal, A.
    Pushpalata Zanwar, Preeti
    Peterson, Rachel
    Kim, Boeun
    Turner, Robert W., II
    Viswanathan, Jaya
    Kulick, Erin R.
    Zuelsdorff, Megan
    Stites, Shana D.
    Arce Renteria, Miguel
    Tsoy, Elena
    Seblova, Dominika
    Ng, Ted K. S.
    Manly, Jennifer J.
    Babulal, Ganesh
    ALZHEIMERS & DEMENTIA, 2023, 19 (07) : 3171 - 3185